Let Your Rabid Leftist Friends And Family Go
Outgoing Biden Admin Exposed for Special Interest Corruption
A Quick Bible Study Vol. 243: What the New Testament Says About Fearing...
The Forever-Tarnished Legacy of Barack Obama
Avoiding Self-Inflicted Trade and Economic Wounds
Giving Thanks Is Good For You
The Hidden Pro-Life Message You Missed at Miss Universe
The Border's Broken Vetting System: Why We Can't Wait to Fix It
Can We Take Back the English Language Now?
Trump's Strategy On Iran Could End Middle East Wars
Trump Names His New Agriculture Secretary
Bombshell Report Reveals Disturbing Truths About the Biden-Harris Parole Pipeline
Gen. Milley Makes Stunning Admission About Incoming Trump Administration
ICE Sends Hochul Grim Warning After Arresting Wanted Illegal Immigrant
Sickening: An Illegal Alien Allegedly Raped a 14-Year-Old Girl in Colorado
OPINION

Novel Therapies to Gut Obamacare

The opinions expressed by columnists are their own and do not necessarily represent the views of Townhall.com.
Advertisement
Advertisement
Advertisement

I discovered OncoMed this week doing searches for new ideas and while we haven't featured the stock yet it's a very compelling story. Targeted approaches to curing cancer became all the rage about a decade ago and while their work has been tedious, success is around the corner. I thought about this company and the uphill battle Republicans face in delaying or defunding the new healthcare law. The real challenge is to find a way to cull out the bad parts and keep the good, except there's so much more of the former.

Advertisement

Our Mission

 OncoMed Pharmaceuticals (OMED)is a development-stage biotechnology company dedicated to improving cancer treatment by discovering and developing monoclonal antibodies and other agents that target the biologic pathways critical to tumor initiating cells, also known as "cancer stem cells". We are leveraging our understanding of these tumor initiating cells to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer. http://www.oncomed.com/

To starve or to delay, that is the question, and it's gnawing at Republicans seeking ways to derail full implementation of Obamacare which is on the eve of its next phase. For a long time I thought it was more rhetoric than reality, this is President Obama's signature accomplishment, after all. But as each day goes by I'm beginning to think there could be a huge groundswell of opposition from all directions. The plan is already having negative consequences on our economy, as there is no doubt in my mind immediate disbandment would add two percentage points to GDP growth. As it stands 2013 has become the year of the Part Time Job and even those are scarce.

I think the general public will turn on this unlikeable law because the big boys that were demonized to sell this in the first place are getting more and more breaks.

First, it was big business and the so-called employer mandate getting a pass on the penalty (tax) of not providing coverage even as individuals will still face such levies.

Advertisement

Now, we've learned limits on out-of-pocket expenses like deductibles and co-pays are going to be skipped for at least a year. The idea was individuals would be capped at $6,350 and families at $12,700 in such costs. Those numbers seem large except when you're suffering from cancer, heart ailments or multiple sclerosis and other ailments that send you to the doctor just about weekly. So, now we have big businesses getting a break and insurance companies getting yet another break, and there are hints unions have some special passes coming real soon, too.

I guess targeting this thing would be like peeling the outer layer of a watermelon and considering the rest the "cancer stem cell."

Maybe it can be de-funded, delayed or just junked.


Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos